Michael J Burke MD
Forensic Psychiatry, Geriatric Psychiatry
Chief Medical Officer Larned State Hospital
Join to View Full Profile
1301 KS Hwy 264Larned, KS 67550
Phone+1 620-285-4580
Fax+1 620-285-4381
Dr. Burke is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Kansas (Wichita)Residency, Psychiatry, 1989 - 1992
University of Kansas School of MedicineClass of 1989
Certifications & Licensure
KS State Medical License 1990 - 2025
American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Evaluation of Demonstrations to End Childhood Hunger - VA Start of enrollment: 2016 Sep 01
Publications & Presentations
PubMed
- 20 citationsConcomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression.Michael J. Burke, Mustafa M. Husain
The Journal of ECT. 2006-09-01 - 25 citationsNumber of risk genotypes is a risk factor for major depressive disorder: a case control studyHolly A. Garriock, Pedro L. Delgado, Mitchel A. Kling, Linda L. Carpenter, Michael J. Burke
Behavioral and Brain Functions. 2006-07-05 - 172 citationsProspective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression.David L. Dunner, A. John Rush, James M. Russell, Michael J. Burke, Stacy Woodard
The Journal of Clinical Psychiatry. 2006-05-15
Lectures
- Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP ConsortiumClinically Relevant Abstract2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
